tacrolimus and Hearing-Loss

tacrolimus has been researched along with Hearing-Loss* in 4 studies

Other Studies

4 other study(ies) available for tacrolimus and Hearing-Loss

ArticleYear
Hearing Impairments as an Overlooked Condition in Kidney Transplant Recipients.
    Transplant international : official journal of the European Society for Organ Transplantation, 2022, Volume: 35

    It is not known whether hearing disorders improves with kidney transplantation. One of the neurotoxic effects of immunosuppressive drugs may be unrecognized hearing loss. In this study, our aim was to evaluate the hearing disorders in kidney transplant patients. Hearing problems in 46 kidney transplant patients [eGFR ≥ 60 ml/min/1.73 m

    Topics: Hearing Loss; Humans; Kidney Transplantation; MTOR Inhibitors; Tacrolimus; Transplant Recipients

2022
A 10-year review of otic lichen planus: the Mayo Clinic experience.
    JAMA dermatology, 2013, Volume: 149, Issue:9

    Lichen planus is an autoimmune inflammatory dermatosis that typically affects the skin but can also involve the stratified squamous epithelium of the external auditory canals and tympanic membranes. Here we report our experience with the clinical presentation, diagnosis, and management of otic lichen planus.. We retrospectively reviewed medical records from January 1, 2001, through May 31, 2011, of patients with a diagnosis of otic lichen planus. Nineteen cases were identified (mean age at diagnosis, 57 years; 15 women). The most common concerns were persistent otorrhea and hearing loss. Other symptoms included plugging, pruritus, tinnitus, pain, and bleeding. The mean symptom duration was 4.0 years (n = 13). Most patients responded well to topical tacrolimus within several months. One patient had a dramatic positive response to rituximab.. Otic lichen planus can lead to persistent hearing loss and should be considered in the differential diagnosis of relentless otorrhea and external auditory canal stenosis. In our experience, topical tacrolimus is the best primary treatment, but alternative therapies could be instituted in severe cases. Early recognition of the nonspecific symptoms of otic lichen planus may lead to prompt treatment and avoidance of irreparable late sequelae.

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Diagnosis, Differential; Ear Canal; Ear Diseases; Female; Follow-Up Studies; Hearing Loss; Humans; Immunologic Factors; Immunosuppressive Agents; Lichen Planus; Male; Middle Aged; Retrospective Studies; Rituximab; Tacrolimus; Treatment Outcome; Tympanic Membrane; Young Adult

2013
Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses.
    British journal of pharmacology, 2012, Volume: 166, Issue:6

    BACKGROUND AND PURPOSE Exposure to an ototoxic level of an aminoglycoside can result in hearing loss. In this we study investigated the otoprotective efficacy of dexamethasone (DXM), melatonin (MLT) and tacrolimus (TCR) in gentamicin (GM)-treated animals and cultures. EXPERIMENTAL APPROACH Wistar rats were divided into controls (treated with saline); exposed to GM only (GM); and three GM-exposed groups treated with either DXM, MLT or TCR. Auditory function and cochlear surface preparations were studied. In vitro studies of oxidative stress, pro-inflammatory cytokine mRNA levels, the MAPK pathway and caspase-3 activation were performed in organ of Corti explants from 3-day-old rats. KEY RESULTS DXM, MLT and TCR decreased levels of reactive oxygen species in GM-exposed explants. The mRNA levels of TNF-α, IL-1β and TNF-receptor type 1 were significantly reduced in GM + DXM and GM + MLT groups. Phospho-p38 MAPK levels decreased in GM + MLT and GM + TCR groups, while JNK phosphorylation was reduced in GM + DXM and GM + MLT groups. Caspase-3 activation decreased in GM + DXM, GM + MLT and GM + TCR groups. These results were consistent with in vivo results. Local treatment of GM-exposed rat cochleae with either DXM, MLT or TCR preserved auditory function and prevented auditory hair cell loss. CONCLUSIONS AND IMPLICATIONS In organ of Corti explants, GM increased oxidative stress and initiated an inflammatory response that led to the activation of MAPKs and apoptosis of hair cells. The three compounds tested demonstrated otoprotective properties that could be beneficial in the treatment of ototoxicity-induced hearing loss.

    Topics: Animals; Anti-Bacterial Agents; Catalase; Dexamethasone; Gentamicins; Hearing Loss; Interleukin-1beta; Male; Melatonin; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type II; Organ of Corti; Protective Agents; Rats; Rats, Wistar; Receptors, Interleukin-1 Type I; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Superoxide Dismutase; Tacrolimus; Tumor Necrosis Factor-alpha

2012
Severe hearing loss after liver transplantation.
    Transplantation proceedings, 2005, Volume: 37, Issue:4

    Little is known about hearing impairment in patients after organ transplantation. Few cases of hearing loss associated with different immunosuppressants have been published. To evaluate severe hearing impairment in patients after liver transplantation (OLT), all living adult patients in need of a hearing aid were analyzed. Out of 521 transplanted patients, 25 (5%) were identified with hearing aids. Nine (36%) of these patients either suffered from hearing loss prior to OLT or experienced risk factors such as ototoxic drugs. Of the remaining 16 patients who developed severe hearing loss after OLT (64%), half were men. Mean age was 42 +/- 18 years at OLT, which took place 8 +/- 4 years ago. Main transplantation indication was virus-induced cirrhosis (44%). In 14/16 (88%) patients, the hearing aid was bilateral. In 50% of patients, the hearing aid was necessary within 2 years post-OLT. Additional tinnitus was present in 9/16 patients (56%), otalgia in three patients (19%). Four patients (25%) reported a history of sudden deafness. In three of them, an association with high levels of calcineurin inhibitors was found. The proportion of patients receiving tacrolimus (50%) was relatively higher than those receiving cyclosporine (50%) compared to control patients (28% respectively 64%, P < .05). In conclusion, a high incidence of severe hearing loss was found in patients after liver transplantation. In most patients, onset of hearing loss is early and bilateral, suggesting a dose-dependent toxicity. The pathogenetic role of different immunosuppressants remains to be evaluated.

    Topics: Adult; Calcineurin Inhibitors; Deafness; Follow-Up Studies; Hearing Aids; Hearing Loss; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Retrospective Studies; Sirolimus; Surveys and Questionnaires; Tacrolimus; Time Factors

2005